Clinical Trial Update: Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial examining how fluconazole and itraconazole affect MLN4924 pharmacokinetics, safety, and tolerability in participants with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Fluconazole (Fluconazole)
• Itraconazole (Itraconazole)
• MLN4924 (pevonedistat)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2019-01-07